Superworth

Parabilis Medicines PBLS

Drug Manufacturers - General, Healthcare
$27.25
−3.78%
Market cap
$3.4B
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
one or more of the four quarters through 2026-06-30 missing
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
one or more of the four quarters through 2026-06-30 missing
Net margin
n/m
one or more of the four quarters through 2026-06-30 missing
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for PBLS, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
$0$0$0$148K
R&D$33.9M$30.1M$37.8M$39.4M
SG&A$6.3M$6.4M$9.7M$11.7M
−$40.2M−$36.5M−$47.5M−$50.9M
Interest expense$399K$396K$292K$210K
Net income−$38.3M−$34.8M−$45.3M−$52.5M
−$23.84−$22.28n/a−$2.32
2M2Mn/a28.9M

Revenue: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

EPS, diluted: Q1 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY25: share-days: the 6-month average less the second quarter's.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Parabilis Medicines' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
PBLSParabilis Medicines$3.4Bn/mn/an/mn/mn/m
OGNOrganon$3.6B18.2×6.0×0.6×−3%3.5%
LQDALiquidia$3.7B30.1×49.4×8.3×n/m30.7%
ARQTArcutis Biotherapeutics$3.9B142×117×8.5×+76%6.1%
NRIXNurix Therapeutics$2.8B11.1×11.0×4.0×n/m42.0%
INDVIndivior Pharmaceuticals$4.3B10.2×19.9×3.1×+16%32.8%
PBHPrestige Consumer Healthcare$2.4B13.9×15.3×2.1×−1%15.6%
HRMYHarmony Biosciences$2.2B12.3×13.8×2.3×+24%18.9%
LGNDLigand Pharmaceuticals$6.1B32.7×37.6×21.1×+55%67.9%
AMRXAmneal Pharmaceuticals$6.5B41.7×51.4×2.1×+9%5.0%
ANIPANI Pharmaceuticals$1.6B15.0×57.5×1.7×+31%11.1%
Peer median$3.7B16.6×28.8×2.7×+20%17.2%

More on Parabilis Medicines

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .